129 related articles for article (PubMed ID: 3773338)
1. Characteristics of the inhibition of ligand binding to serotonin receptors in rat brain membranes by verapamil.
Adachi H; Shoji T
Jpn J Pharmacol; 1986 Aug; 41(4):431-5. PubMed ID: 3773338
[TBL] [Abstract][Full Text] [Related]
2. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.
Hoyer D; Engel G; Kalkman HO
Eur J Pharmacol; 1985 Nov; 118(1-2):13-23. PubMed ID: 2935410
[TBL] [Abstract][Full Text] [Related]
3. Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets.
Affolter H; Burkard WP; Pletscher A
Eur J Pharmacol; 1985 Jan; 108(2):157-62. PubMed ID: 3156755
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
Titeler M; Lyon RA; Davis KH; Glennon RA
Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective blockade of central [3H]5-hydroxytryptamine binding to multiple sites (5-HT1A, 5-HT1B and 5-HT1C) by mianserin and propranolol.
Alexander BS; Wood MD
J Pharm Pharmacol; 1987 Aug; 39(8):664-6. PubMed ID: 2888864
[TBL] [Abstract][Full Text] [Related]
6. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.
Pranzatelli MR
Biochem Pharmacol; 1991 Aug; 42(5):1099-105. PubMed ID: 1872895
[TBL] [Abstract][Full Text] [Related]
7. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
Appel NM; Mitchell WM; Garlick RK; Glennon RA; Teitler M; De Souza EB
J Pharmacol Exp Ther; 1990 Nov; 255(2):843-57. PubMed ID: 2243353
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
Hargreaves AC; Gunthorpe MJ; Taylor CW; Lummis SC
Mol Pharmacol; 1996 Nov; 50(5):1284-94. PubMed ID: 8913360
[TBL] [Abstract][Full Text] [Related]
9. Influence of lipid peroxidation on [3H]ketanserin binding to 5-HT2 prefrontal cortex receptors.
Rego AC; Oliveira CR
Neurochem Int; 1995 Dec; 27(6):489-96. PubMed ID: 8574178
[TBL] [Abstract][Full Text] [Related]
10. Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography.
Fischette CT; Nock B; Renner K
Brain Res; 1987 Sep; 421(1-2):263-79. PubMed ID: 3690273
[TBL] [Abstract][Full Text] [Related]
11. [3H]ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes.
Hoyer D; Vos P; Closse A; Pazos A; Palacios JM; Davies H
Naunyn Schmiedebergs Arch Pharmacol; 1987 Mar; 335(3):226-30. PubMed ID: 2884572
[TBL] [Abstract][Full Text] [Related]
12. 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA).
Shannon M; Battaglia G; Glennon RA; Titeler M
Eur J Pharmacol; 1984 Jun; 102(1):23-9. PubMed ID: 6479216
[TBL] [Abstract][Full Text] [Related]
13. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors.
Bischoff S; Heinrich M; Sonntag JM; Krauss J
Eur J Pharmacol; 1986 Oct; 129(3):367-70. PubMed ID: 3536532
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of [3H]spiperone binding to 5-HT2 receptors of rat cerebral cortex by the calcium antagonists verapamil and D600.
Taylor JE; Defeudis FV
Eur J Pharmacol; 1984 Oct; 106(1):215-6. PubMed ID: 6529970
[No Abstract] [Full Text] [Related]
15. Two classes of [3H]spiperone binding sites in bovine neurohypophysis: D-2 receptors and putative 5-HT2 receptors.
Treiman M; Andersen PH
J Recept Res; 1989; 9(4-5):297-312. PubMed ID: 2574236
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus.
Clineschmidt BV; Reiss DR; Pettibone DJ; Robinson JL
J Pharmacol Exp Ther; 1985 Dec; 235(3):696-708. PubMed ID: 2934542
[TBL] [Abstract][Full Text] [Related]
17. Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors.
Motulsky HJ; Snavely MD; Hughes RJ; Insel PA
Circ Res; 1983 Feb; 52(2):226-31. PubMed ID: 6297831
[TBL] [Abstract][Full Text] [Related]
18. (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
Hofmann HP; Raschack M; Unger L
Arzneimittelforschung; 1989 Mar; 39(3):304-8. PubMed ID: 2757655
[TBL] [Abstract][Full Text] [Related]
19. Non-serotonergic 3H-ketanserin binding sites in human platelets: characteristics and interaction with calcium antagonists.
Oliva D; Pocchiari F; Allievi L; Rovati GE; Nicosia S
Pharmacol Res; 1992 Sep; 26(2):187-99. PubMed ID: 1409259
[TBL] [Abstract][Full Text] [Related]
20. Binding of the putative anxiolytic TVX Q 7821 to hippocampal 5-hydroxytryptamine (5-HT) recognition sites.
Glaser T; Traber J
Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):211-5. PubMed ID: 3160954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
